Evome Medical Technologies Inc.
LNDZF
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.34M | 7.70M | 8.95M | 11.56M | 14.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.34M | 7.70M | 8.95M | 11.56M | 14.65M |
| Cost of Revenue | 4.73M | 5.28M | 6.04M | 7.49M | 9.23M |
| Gross Profit | 2.61M | 2.42M | 2.91M | 4.07M | 5.42M |
| SG&A Expenses | 2.35M | 2.70M | 4.03M | 4.12M | 5.29M |
| Depreciation & Amortization | 592.30K | 596.90K | 752.90K | 920.10K | 883.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.67M | 8.58M | 10.82M | 12.53M | 15.40M |
| Operating Income | -334.30K | -876.50K | -1.87M | -971.00K | -756.70K |
| Income Before Tax | -842.70K | -1.66M | -3.18M | -11.62M | 2.24M |
| Income Tax Expenses | 0.00 | 8.60K | -- | 6.60K | 7.10K |
| Earnings from Continuing Operations | -842.70K | -1.67M | -3.18M | -11.62M | 2.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -842.70K | -1.67M | -3.18M | -11.62M | 2.23M |
| EBIT | -334.30K | -876.50K | -1.87M | -971.00K | -756.70K |
| EBITDA | -84.10K | -622.10K | -1.51M | -479.40K | -86.10K |
| EPS Basic | -0.01 | -0.02 | -0.04 | -0.15 | 0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | 0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.04 | -0.15 | 0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | 0.01 | 0.00 |
| Average Basic Shares Outstanding | 91.16M | 91.16M | 86.05M | 79.37M | 77.98M |
| Average Diluted Shares Outstanding | 91.16M | 91.16M | 86.05M | 79.37M | 77.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |